RxDoctor Payments Data

Ashley Dahl, MD

Ophthalmology · Vestavia Hills, ALNPI 1750546545

Payments from drug & device makers

$2,824in general payments, 2019–2025

Across 123 payments — averaging $22.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$889
  • Alcon$558
  • Kala Pharmaceuticals, Inc.$438
  • Sun Pharmaceutical Industries Inc.$209
  • Shire North American Group Inc$118
  • Novartis$115
  • plus $496 from 8 others

What the payments were for

  • Food & beverage$2,824100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,824 in reported general payments places this provider in the 60th percentile of 197 ophthalmology providers in Alabama.

See all ophthalmology providers in Alabama

Medicare billing

Part B allowed, 2024
$174,741
Medicare patients
707
Services billed
1,830

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine158$169,446
Cyclosporine98$57,036
XiidraLifitegrast16$19,862
LumiganBimatoprost55$17,325
Bromfenac Sodium75$9,737
Latanoprost531$9,069
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol31$6,617
ProlensaBromfenac Sodium19$6,359
MoxifloxacinMoxifloxacin Hcl175$5,683
Prednisolone Acetate172$5,608
Travoprost16$3,774
Brimonidine Tartrate51$3,066
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat99$2,103
Timolol Maleate129$1,654
ValacyclovirValacyclovir Hcl35$1,551

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$889$186,772213 claims
Bausch & Lomb Americas Inc.Xiidra$111$19,86216 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa$114$6,35919 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 197 ophthalmology providers in Alabama.

Other ophthalmology in Vestavia Hills

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →